FT536 + atezolizumab

FT536 + atezolizumab is an experimental combination therapy being evaluated for advanced solid tumors. **FT536** is a first-in-class, gene-edited, off-the-shelf natural killer (NK) cell therapy derived from induced pluripotent stem cells (iPSC) and engineered with a chimeric antigen receptor (CAR) targeting the α3 domain of the stress-induced ligands MICA and MICB, which are commonly expressed on tumor cells. FT536 also expresses a high-affinity, non-cleavable CD16 receptor to enhance antibody-dependent cellular cytotoxicity (ADCC) when used with monoclonal antibodies, such as **atezolizumab**. **Atezolizumab** is a PD-L1 immune checkpoint inhibitor monoclonal antibody that blocks the interaction of PD-L1 with PD-1, thereby augmenting anti-tumor immune responses. The combination is designed to leverage both innate and adaptive immune mechanisms: FT536 directly recognizes and kills tumor cells via CAR engagement and can mediate enhanced ADCC in the presence of atezolizumab, while atezolizumab prevents suppression of immune responses by blocking the PD-L1 axis[1][2][4].

Other names

FT536FT-536FT 536